[{"address1": "9350 Kirby Drive", "address2": "Suite 300", "city": "Houston", "state": "TX", "zip": "77054", "country": "United States", "phone": "713 400 6400", "website": "https://markertherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Juan F. Vera M.D.", "age": 43, "title": "Co-Founder, CEO, President, Treasurer, Secretary & Director", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 399251, "exercisedValue": 0, "unexercisedValue": 39127}, {"maxAge": 1, "name": "Ms. Elizabeth  Donnelly", "title": "Director of Administration", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Maria-Bernadette  Madel", "age": 33, "title": "Director of Corporate Operations & External Communications", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Cheung", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Monic  Stuart M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Patricia  Allison", "title": "Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary  Newman Ph.D.", "age": 64, "title": "Head of Regulatory Affairs", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Z. Florkiewicz Sr.", "title": "Senior Director of Molecular Biology & Virology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.95, "open": 1.97, "dayLow": 1.73, "dayHigh": 1.97, "regularMarketPreviousClose": 1.95, "regularMarketOpen": 1.97, "regularMarketDayLow": 1.73, "regularMarketDayHigh": 1.97, "beta": 1.492, "forwardPE": -0.80821913, "volume": 241555, "regularMarketVolume": 241555, "averageVolume": 70041, "averageVolume10days": 99880, "averageDailyVolume10Day": 99880, "bid": 1.37, "ask": 2.25, "bidSize": 200, "askSize": 200, "marketCap": 20882636, "fiftyTwoWeekLow": 1.65, "fiftyTwoWeekHigh": 5.99, "priceToSalesTrailing12Months": 5.6024146, "fiftyDayAverage": 3.0494, "twoHundredDayAverage": 3.68615, "currency": "USD", "enterpriseValue": 19592210, "profitMargins": -2.78222, "floatShares": 6762778, "sharesOutstanding": 10709000, "sharesShort": 69997, "sharesShortPriorMonth": 55784, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0078, "heldPercentInsiders": 0.12199, "heldPercentInstitutions": 0.2244, "shortRatio": 1.55, "shortPercentOfFloat": 0.0109, "impliedSharesOutstanding": 11798100, "bookValue": 1.58, "priceToBook": 1.1202531, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -10307587, "trailingEps": -0.97, "forwardEps": -1.46, "lastSplitFactor": "1:10", "lastSplitDate": 1674777600, "enterpriseToRevenue": 5.256, "52WeekChange": -0.5400944, "SandP52WeekChange": 0.21027291, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MRKR", "underlyingSymbol": "MRKR", "shortName": "Marker Therapeutics, Inc.", "longName": "Marker Therapeutics, Inc.", "firstTradeDateEpochUtc": 1026826200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f52316f7-d523-378a-bebe-a89c89d1c289", "messageBoardId": "finmb_1725474", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.77, "targetHighPrice": 19.0, "targetLowPrice": 19.0, "targetMeanPrice": 19.0, "targetMedianPrice": 19.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 7800464, "totalCashPerShare": 0.874, "quickRatio": 5.218, "currentRatio": 5.92, "totalRevenue": 3727435, "revenuePerShare": 0.42, "returnOnAssets": -0.40866002, "returnOnEquity": -0.71736, "grossProfits": -5845308, "freeCashflow": -7401172, "operatingCashflow": -10899731, "revenueGrowth": 0.533, "grossMargins": -1.56819, "operatingMargins": -1.97399, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]